Precise Medicine of Restrictive Cardiomyopathy

QianYun Wu, Iokfai Cheang, XinLi Li

Abstract

Restrictive Cardiomyopathy (RCM) is a form of cardiomyopathy, which having improper blood filling by different restricted etiologies. RCM can be clinically challenging and often result of a poor prognosis. With the early and precise intervention, expectancy outcomes are better. In this article, we reviewed an updated of restrictive cardiomyopathy which are published and provide an overview diagnosis and treatment advancement of the disease.

Key words: Restrictive cardiomyopathy (RCM); Precise Medicine; Diagnosis; Treatment

© 2018 The Author(s). Published by ACT Publishing Group Ltd. All rights reserved.
Endocardial diseases include drug-induced restrictive cardiomyopathy, hematologic diseases (eq. Sickle cell anemia,), carcinoid, medication-induced (serotonin, ergotamine), and chemotherapy-induced (anthracyclines).

Other rare causes, such as post viral myocarditis[12], diabetic cardiomyopathy mainly describe a restrictive phenotype with concentric LV remodeling and diastolic LV dysfunction[13]. Types of muscular dystrophies with cardiac involvement comprises can also behaved as RCM[13].

### Pathophysiology

#### 1. Primary RCM
The pathogenesis of primary RCM is mainly due to the increased sensitivity of muscle filament to calcium and the accumulation of desmin and type III collagen[14,15]. Familial cases are commonly manifested AD inheritance with incomplete penetrance.

There are over 20 reported genes were shown to be associated with RCM, but familial RCM caused by single gene defect is the least common. Genes have been discovered to be associated with the primary RCM including troponin (cTnI and cTnT), myosin binding protein C (MyBP-C), myosin light chain 3 (MYL2, MYL3), desmin (DES), myopalladin (MYPN), etc[16].

For the mutation of the genes which encoding sarcomeric proteins and cytoskeletal protein gene leaded to RCM, it could also cause hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM). RCM was often considered as an extreme form of HCM[16]. Previous studies have shown that confirmed gene mutation rate was only 30% in RCM. In two other smaller scale studies showed the incidence of familial inheritance idiopathic RCM was up to 75%[10].

Specific pathogenic genes are shown in table 1.

#### 2. Secondary RCM

**2.1. Cardiac amyloidosis (CA)**
Cardiac amyloidosis is often caused by a group of diseases resulting by the misfolded protein. The misfolded soluble extracellular proteins and insoluble fibrils deposited in the myocardial tissues, leading to both structural and functional disruptions. Based on the nature of the fibril precursor protein and associated clinical features, CA is divided into 5 different types (Table 2)[16], in which AL and ATTR are closely related to cardiac disorders.

**2.1.1 Amyloid light-chain (AL) amyloidosis**
AL amyloidosis, also named as primary amyloidosis, is associated with monoclonal gamopathy of undetermined significance or plasma cell dyscrasias, most common in multiple myeloma. Cardiac involvement usually indicated poor prognosis, over half of the patients developed heart failure in early stage. Even with early chemotherapy, the median survival time of AL amyloidosis patients with HF was less than 6 months[17].

**2.1.2 Cardiac Transthyretin Amyloidosis (ATTR)**
ATTR is caused by extracellular deposition of amyloid fibrils from liver-derived transthyretin (TTR), including mutant (m-TTR) and wild type (wt-TTR).

### Table 1 Possible pathogenic gene of RCM.

| Abbr. | Name | Gene ID |
|-------|------|---------|
| TNNI3 | Troponin I3 | 7137 |
| TNNT2 | Troponin T2 | 7139 |
| TNNC1 | Troponin C1 | 7134 |
| TPM1 | Tropomyosin 1 | 7168 |
| MYL2 | Myosin Light Chain 2 | 4633 |
| MYL3 | Myosin Light Chain 3 | 4634 |
| ACTC1 | Alpha-cardiac Actin | 70 |
| MYBPC3 | Myosin Binding Protein C, cardiac | 4607 |
| TTN | Titin | 7273 |
| DES | Desmin | 1674 |
| MYPN | Myopalladin | 84665 |
| CryAB | Crystallin Alpha B | 1410 |
| BAG3 | Bcl-2-Associated Athanogene3 | 9531 |
| FLNC | Filamin-C | 2318 |
| TNN | Tenascin N | 63923 |
| SMAD | SMAD Family Member 4 | 4089 |
| MYH7 | Myosin Heavy Chain 7 | 4625 |
| SYNE2 | Spectrin Repeat Containing Nuclear Envelope Protein 2 | 23224 |
| JUP | Junction Fakogoblin | 3728 |
| ACTN2 | Actinin Alpha 2 | 88 |

### Table 2 Types of Cardiac Amyloidosis.

| Type | Precursor Protein | Producing Area | Involved tissue |
|------|------------------|----------------|----------------|
| AL Amyloidosis | Light Chain Fragments | Bone Marrow | Liver, Kidney, Heart, Nervous System, Soft Tissue |
| M-TTR Amyloidosis | Mutated Transthyretin | Liver | Heart, Nervous System, |
| W1-ATTR Amyloidosis (Senile CA) | Wild-type Transthyretin | Liver | Heart |
| AA Amyloidosis | Serum Amyloid Protein A (SAA) | Stress Reactants | Heart, Kidney, Liver |
| Isolated Atrial Amyloidosis (IAA) | Atrial Natriuretic Peptide (ANP) | Atrium | Atrium |

### Table 3 Other Common Associated Diseases and Genes of Secondary RCM.

| Diseases | Mode of Inheritance | Genes |
|----------|---------------------|-------|
| Systemic sclerosis | Multifactorial | PTPN22, MCFP1, IL-1a, IL-10, IL-13, FAS, AIF1, IL13RA2, SPARC, FBN1, TOPOI |
| Pseudoxanthoma Elasticum | AR | ARCC6 |
| sarcoidosis | Multifactorial | BNL1, ANXA11 |
| Gaucher disease | AR | GBA |
| Hurler disease | AR | IDUA |
| Glycogen storage disease | Usually AR | G6PC, SLC37A4, NPT4, GAA, AGL, GBE, PYGM, PYGL, PFKM, PBK, PBKPHKA2, PBKPHKB, PHK2, PBK, PBKPHKA1, PHKA1, PHKG1, GYS2, GYS1 |
| Fabry disease | XR | GLA |
| Hemochromatosis | AD / AR | HFE, HFE2, HAMP, TFR2, SCL40A1 |
| Hereditary amyloidosis | AD | TTR, CST3, GSN, LYZ, APOA1, APOA2, PGA |
(1) Mutant TTR Amyloidosis (m-TTR): m-TTR is a systemic autosomal dominant disorder due to tissue deposition of various proteins, including apolipoproteins A-I and A-II, and TTR. It is often associated with peripheral or autonomic neuropathy. Cardiac involvements are often less aggressive than AL amyloidosis\(^{[19]}\).

(2) Wild Type TTR Amyloidosis (wt-TTR): Wild Type TTR Amyloidosis was previously known as senile amyloidosis. Study showed at the autopsy of individuals over 80 years old, about 8% to 16% had cardiac amyloid deposition. Compared with primary amyloidosis, the prognosis of wt-TTR is better, with a median survival time of 6 years\(^{[18]}\).

(3) Including AA amyloidosis, atrial associated amyloidosis and apolipoproteins A-I/ A-II associated amyloidosis are lesscommon types of CA. Cardiac amyloid deposition also can occur in isolated atrial and dialysis-related (b2 microglobulin) amyloidosis. Although isolated atrial amyloidosis is associated with development of atrial fibrillation and/or other localized lesions presentation, HF is less common in these types\(^{[20]}\).

2.1.3 Other types of secondary RCM

Most are gene related. The mode of inheritance depends on the disease and mutant genes\(^{[19]}\). The discovered associated genes are shown below on Table 3\(^{[20]}\). The discovered associated genes are shown below on Table 3\(^{[20]}\).

**DIAGNOSIS**

For patients whose clinical history and physical examination indicating a suspected RCM, ECG and echocardiogram are routine for the evaluation and differential diagnosis. The suspicion of RCM could be supported by various tests of the usual causes; such as the free light chain in serum and urine indicating the diagnosis of CA, hemochromatosis, hypereosinophilia syndrome, etc. Also Cardiac MRI (CMR), biopsy, and genetic screening contribute to the precision diagnosis of RCM, which are particularly important to exclude the secondary causes and establish to optimal regimen. At present stage, genetic diagnosis and treatment of RCM are continuously expanding according to novel mutations. Following paragraphs focused on the preliminary diagnosis and precise diagnosis of RCM. The flow chart is illustrated in figure 1.

1. Preliminary Diagnosis

1.1. ECG & UCG

Electrocardiogram (ECG) of RCM patients commonly present with low voltage of limb and left chest leads (V5, V6), pseudo infarction, and poor R wave progression in chest leads.

Echocardiography (UCG) as a routine examination has a great significance, when any of the following manifestations occurred in the absence of other plausible causes, the diagnosis of RCM a highly possible. (1) End-diastolic LV wall thickness greater than 12 mm; (2) Granular sparkling appearance of the myocardium; (3) Increased thickness of atrioventricular valves, right ventricular free wall, or interatrial septum; (4) Pericardial effusion.

In addition, there are different characteristic could be observed in corresponding etiology. Constrictive pericarditis can be seen an atrioventricular septal incisure and a reduce coordination of ventricular movement. In hypertrophic cardiomyopathy, ventricular diastolic compliance decreased and the lesions mainly involving the interventricular septum. Mural thrombi often observe in hypereosinophilia syndrome. However, for patients with ultrasound features suggesting a constricted cardiac disease, results should be combined with other test to investigate etiology and diagnosis.

1.2. Cardiac magnetic resonance (CMR)

CMR, with late gadolinium enhancement (LGE) and T1 mapping, is emerging as a reference standard for diagnosis and characterization of cardiac amyloidosis\(^{[21]}\), and providing transparent view of disease evaluation and morphological characteristics.

The cardiac structure of RCM is characterized by normal or reduced ventricular volume, normal or slight thickening of ventricular wall thickness, enlarged double chamber and normal pericardium in T1W1 and T2W1 sequences. In sub-endocardial and mid-myocardial, LGE as a characteristic manifestation are indicated the existence of myocardial fibrosis. In typical CA, CMR can show diffuse endocardial LGE, simultaneously involving the all four chambers but the mid-layer does not involve, and intuitively display the CA infiltration area. Study by Ana Martinez-Naharro, et al\(^{[23]}\) support the view that using CMR as typical LGE imaging for cardiac ATTR. Moreover, CMR with extracellular volume fraction (ECV) correlated with amyloid burden was found to be an independent prognostic factor for survival in patients with ATTR.

1.3. Others

Radionuclide myocardial imaging (ECT) contributes to diagnose RCM. It has been suggested that the preferential binding to ATTR might be a result of higher calcium content and could be considered a diagnostic standard for ATTR\(^{[22]}\).

Cardiac catherization is not only for the differential and functional diagnosis; the value of evaluating both pre-operative indications and post-operative condition for heart transplantation is major either. By measuring LVEDP as well as other parameters in assessing pulmonary vascular resistance is considered the gold standard for determination of diastolic parameters\(^{[24]}\).

Figure 1 Flow Chart for Diagnosis of RCM.
### 2. Precise Diagnosis
#### 2.1. Pathological Diagnosis
Including bone marrow biopsy and endomyocardial biopsy (EMB), pathology evidences are considered the golden standard for the diagnosis of RCM. Endomyocardial biopsy can achieve nearly 100% sensitivity if minimum of 4 or more samples are obtained during the biopsy procedure[23]. It could provide a transparent view of the etiology, therefore EMB should be considered when the pathogenesis of heart failure cannot be determined by noninvasive testing. Especially, when suspecting of infiltrative disease and rare cardiomyopathy, such as suspected hypersensitivity myocarditis, anthracycline cardiomyopathy, cardiac tumors, and arrhythmogenic right ventricular cardiomyopathy (ARVC), etc.[24]

However, not all hospitals are eligible for myocardial biopsy. Bone marrow biopsy could use to confirm the diagnosis of amyloidosis; mass spectrometry analysis is further used to identify amyloid type. Rectal, gastrocnemius, labial gland, and fat aspiration biopsy should be used as the secondary choice when myocardial biopsy is not available[27].

#### 2.2. Genetic diagnosis
The genetic diagnosis of RCM is recommended in European guidelines (IIB)[40], with the rising consciousness of precise medicine. In the clinical application, it recommends that the etiopathogenesis and diagnosis depend on identified pathogenic mutations in the proband; and for the proband that could not locate the pathogenic mutations but cannot exclude the possibility of genetic disease, the incidence of autosomal dominant pathogenicity was significantly lower than those found in pathogenic mutations. Detection of these 8 target genes: JUP, DES, BAG3, ACTN2, MYH7, TNNT2, TNNI3 and MYBPC3 are recommended[28].

### 3. Antidiastole of Constrictive Pericarditis
Due to the similar clinical features of constrictive pericarditis (CP) and RCM, there is high rate of clinical misdiagnosis and it is important to differentiate them carefully. In developed countries, the most common reported causes of CP respectively were idiopathic or viral, post-radiation therapy, connective tissue disorder, and post-cardiac surgery[40]. On the other hand in developing countries, tuberculosis infection is a major cause besides the above. In addition to the different etiology, other diagnostic evaluation including ECG, echocardiography, cardiac imaging characteristics, and cardiac catheterization could have different presentation which listed below (Table 4, Modified from Imazio et al[41]).

| Diagnostic evaluation | Constrictive Pericarditis | Restrictive Cardiomyopathy |
|-----------------------|---------------------------|----------------------------|
| **Physical Findings** | Kussmaul sign, pericardial knock | Regurgitant murmur, Kussmaul sign may be present, S3 (advanced). |
| **ECG** | Low voltages, non-specific ST/T changes, atrial fibrillation. | Low voltages, pseudo-infarction, possible widening of QRS, left-axis deviation, atrial fibrillation. |
| **Chest X-ray** | Pericardial calcifications (1/3 of cases) | No pericardial calcifications. |
| **Echocardiography** | Septal bounce. | Small left ventricle with large atria, possible increased wall thickness. |
| | Pericardial thickening and calcifications. | E/A ratio >2, short DT. |
| | Respiratory variation of the mitral peak E velocity of >25% and variation in the pulmonary venous peak D flow velocity of >20% | Significant respiratory variations of mitral inflow are absent. |
| | Colour M-mode flow propagation velocity (Vp) >45 cm/sec. | Colour M-mode flow propagation velocity (Vp) > 45 cm/sec. |
| **Cardiac Catheterization** | “Dip and plateau” or “square root” sign, right ventricular diastolic, and left ventricular diastolic pressures usually equal, ventricular interdependence (i.e. assessed by the systolic area index >1.1). | Tissue Doppler: peak e’ > 8.0 cm/s. |
| **CT/CMR** | pericardial thickness >3-4mm, pericardial calcifications (CT), ventricular interdependence (real-time cine CMR). | Normal pericardial thickness (< 3.0 mm), myocardial involvement by morphology and functional study (CMR). |

#### TREATMENT

**1. Primary RCM:**
Up to now, heart transplantation is as the one and only effective treatment for RCM. With the improvement of gene engineering technology, the mutation of RCM would provide the basis for precise treatment which needs further clinical trials.

Gene therapy improve the heart function of heart failure by inhibiting the expression of G protein-coupled kinases (GRK2) has been succeed[31], which provides new perspectives of the cardiomyopathy treatments. By inhibiting the overexpression of SERCA2a gene to regulate the calcium reserving of the heart, it regulated and controlled the development of heart failure which also might delay the progress of RCM[30].

Gene repairmen or deletion to mutation of primary RCM with viral vector are the future target of therapy, which need further clinical trials to demonstrate it. The gene therapy using adeno-associated virus (AAV) to transform through virus engineering as a carrier has been recognized[31]. Further exploration of the usage and mechanisms are needed.

**2. Secondary RCM:**
The treatments of primary disease combine with the basis of the clinical characteristics to build up the optimum therapy for different types are considered in secondary RCM.

For endometriol fibrosis, the treatment is mainly to improve the symptoms of heart failure. Spironolactone is the first choice of diuretic, which can prevent further progression of fibrosis and improve outcomes in addition to the pathophysiological role[25]. Surgical resection and atroventricular valve repair are feasible and could increase survival rate[30].

Bortezomib-based regimens for light chain cardiac amyloidosis.
(AL-CA) are now considered to be the preferred treatment option for its near complete remission of plasma cell dyscrasias[34]. With early recognition and treatment with targeted plasma cell therapy, AL-CA can be managed effectively. Gene-silencing therapy for amyloidosis has also evolved, such as anti-serum amyloid P (SAP) component, which has experienced preclinical and early clinical success in amyloid deposits scavenging from affected organs[39]. For end stage patient, cardiac transplantation combined with chemotherapy or targeted drug therapy could reduce the recurrence.

Clinical trials from the various pathological pathways of reducing amyloid protein production in m-TTR are currently in progress[39], including stabilizing four TTR dimer to interfere protein decomposition to degrade amyloid fiber[37]; doxycycline and tauroursodeoxycholic acid; small interfering RNA (SiRNA) and monoclonal antibody therapy, etc. Among the above SiRNA and ASOS gene suppressor therapy in amyloidosis disease model has one of the most promising aspects. Liver involvement suggests early orthotopic liver transplantation; combined heart-liver transplantation if available, which could reduce cardiac sudden death[39].

Such as eosinophilia, etiological treatment includes corticosteroids and (or) with inatim, anticoagulant therapy, the treatment of heart failure and end-stage heart transplantation[39].

PROGNOSIS
The complexity and diversity of RCM etiology make it has worst prognosis of cardiomyopathy. Current staging systems for AL-CA are based on serum levels of NT-pro-BNP, cardiac troponin T, and the concentration of circulating free light chains. The combination of the 3 biomarkers constitutes the most powerful prognostic tool available in AL-CA and is the basis for the staging systems elaborated by the Mayo Clinic. The scoring system assigns 1 point for each of the following: NT-pro-BNP ≥ 1800 pg/mL, troponin T ≥ 0.025 ng/mL, and difference between the κ and λ free light chains ≥ 18 mg/dL. Median survival of stage III patients was only 3.5 to 4.1 months. Patients with pronounced elevations of both NT-pro-BNP and troponin have a particularly poor prognosis[29].

CONCLUSION
For patients with RCM, the early and accurate diagnosis reflexes a great clinical outcome. Preliminary diagnosis once confirmed cardiomyopathy; for any suspicion of primary RCM patient, known mutation carriers and their family members, genetic screening is necessary. Genetic diagnosis and treatment technique of heart disease are emerging and rising. The genetic diagnosis has a high clinical value for early diagnosis, risk stratification, and prognostic evaluation of RCM patients; while genetic treatment provides a new promising way for RCM patients. Overall, both could provide a significant improvement the prognosis of patients with RCM and needed a further exploration in clinical practices.

REFERENCE
1. Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E, Thaman R, Mogensen J, Elliott PM. [DOI Y, McKenna WJ. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. Journal of the American College of Cardiology 2007; 49(25): 2419-2426. [DOI: 10.1016/j.jacc.2007.02.061]; [PMID: 17599605]
2. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121(7); 819-837. [DOI: 10.1161/CIRCRESAHA.117.310982]; [PMID: 28912185]
3. Garcia MJ. Constrictive pericarditis versus restrictive cardiomyopathy? J Am Coll Cardiol 2016; 67(17): 2061-2076. [DOI: 10.1016/j.jacc.2016.01.076]; [PMID: 27126534]
4. Geske JB, Anavekar NS, Nishimura RA, Oh JK, Gersh BJ. Differentiation of constriction and restriction: complex cardiovascular hemodynamics. J Am Coll Cardiol 2016; 68(21): 2329-2347. [DOI: 10.1016/j.jacc.2016.08.050]; [PMID: 27884252]
5. Malcij I, Jelusic M, Kniwei H, Barici S, Jelasic D, Bozijko Z. Epidemiology of cardiomyopathies in children and adolescents: a retrospective study over the last 10 years. Cardiol Young. 2002; 12(3): 253-259; [PMID: 12365172]
6. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988; 318: 1355-1362. [DOI: 10.1056/NEJM198805263182103]; [PMID: 3367936]
7. Jurcuţ RO, Bastian A E, Militaru S, Popa A, Manole E, Popescu BA, Talijila J, Popescu BO, Gihinck CD. Discovery of a new mutation in the desmin gene in a young patient with cardiomyopathy and muscular weakness. Rom J Morphol Embryol. 2017; 58(1): 225-230. [PMID: 28523323]
8. Seferovi PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. European Heart Journal. 2015; 36(27): 1718. [DOI: 10.1093/eurheartj/ehv134]; [PMID: 25888006]
9. Zhang J, Kumar A, Stalker HJ, Virdi G, Ferrans VJ, Horiba K, Fricker FJ, Wallace MR. Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy Clin Genet. 2001; 59: 245-256. [DOI: 10.1034/j.1399-0004.2001.590406.x; PMID: 11296890]
10. Davis J, Wen H, Edwards T, Metzger JM. Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutations J Mol Cell Cardiol. 2008; 44(5): 891-904. [DOI: 10.1016/j.yjmcc.2008.02.074]; [PMID: 18423639]
11. Yamoto F, Lu QW, Morimoto S, Tanaka H, Kono N, Nagata K, Ojima T, Takahashi-Yanaga F, Miya W, Sasaguri T, Nishita K, Tanokura M, Ohtsuki I. Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem Biophys Res Commun. 2005; 338(3): 1519-26. [DOI: 10.1016/j.bbrc.2005.10.116]; [PMID: 16288990]
12. Gu Q, Mendsaikhan U, Khuchua Z, Jones BC, Lu L, Towbin JA, Xu B, Purevjav E. Dissection of Z-disc myopalladin gene network involved in the development of restrictive cardiomyopathy using system genetics approach. World J Cardiol 2017; 9(4): 320-331. [DOI: 10.4330/wjc.v9.i4.320]; [PMID: 28515850]
13. Hinton RBMichelfelder EC, Marino BS, Bove KE, Ware SM. A fetus with hypertrophic cardiomyopathy, restrictive, and single-ventricle physiology, and a beta-myosin heavy chain mutation. Journal of Pediatrics. 2010; 157(1): 164-166. [DOI: 10.1016/j.jpeds.2010.02.044]; [PMID: 20394946]
14. Gallego-Delgado M, Delgado JF, Brossa-Loidi V, Palomo J, Marzua-Rivas P, Perez-Villa F, Salazar-Mendaguchia J, Ruiz-Cano MJ, Gonzalez-Lopez E, Padron-Barthe L, Bornstein B, Alonso-Pulpun L, Garcia-Pavia P. Idiopathic restrictive cardiomyopathy is primarily a genetic disease. J Am Coll Cardiol. 2016; 67(25): 3021-3023. [DOI: 10.1016/j.jacc.2016.04.024]; [PMID: 27339502]
15. Kostareva A, Kiselev A, Gudkova A, Frisman G, Ruepp A, Frisman D, Smolina N, Tarnovskaia S, Nilsson D, Zlotina A, Khodyuchenko T, Vershinina T, Pervunina T, Klyushina A, Kozenkow A, Sjoberg G, Golovljeva I, Sejersen T, Slyakhko E. Genetic spectrum of Idiopathic restrictive cardiomyopathy uncovered by next-generation sequencing. PLoS One. 2016;
11(9): e016332. [DOI: 10.1371/journal.pone.016332]; [PMID: 27662471]

16. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollub M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsmarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP; Heart Rhythm Society (HRS); European Heart Rhythm Association (EHRA). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011; 13(8): 1077-1109. [DOI: 10.1093/eurheartj/het045]; [PMID: 21810866]

17. Sperry BW, Tang WHW. Amyloid heart disease: genetics translated into disease-modifying therapy. Heart. 2017; 103(11): 812-817. [DOI: 10.1136/heartjnl-2016-309914]; [PMID: 28255101]

18. Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz MA, Goldstein BH. Utility of Echocardiography in the Assessment of Restrictive Cardiomyopathy. Circ Heart Fail. 2011; 4(4): 676-684. [DOI: 10.1002/humu.22942]; [PMID: 26666891]

19. Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth Freitag TB, Halushka MK, Russell SD. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013; 6(4): 676-684. [DOI: 10.1161/CIRCHEARTFAILURE.112.000087]; [PMID: 23733916]

20. Siddiqi OK, Ruberg FL. Challenging the myths of cardiac amyloidosis. Eur Heart J. 2017; 38(24): 1909-1912. [DOI: 10.1093/eurheartj/ehx210]; [PMID: 28444296]

21. Sturm AC. Genetic testing in the contemporary diagnosis of cardiomyopathy. Curr Heart Fail Rep. 2013; 10(1): 63-72. [DOI: 10.1007/s11897-012-0124-6]; [PMID: 23135967]

22. Canvavo A, Komici K, Benevenga L, D’amicco ML, Gambino G, Liccado D, Ferrara N, Rengo G. GRK2 as a therapeutic target for heart failure. Expert Opin Ther Targets. 2018 Jan; 22(1): 75-83. [DOI: 10.1080/14728222.2018.1406925]; [PMID: 29166798]

23. Pellikka PA, Holmes DR Jr, Edwards WD, Nishimura RA, Tajik AJ, Freitag TB, Halushka MK, Russell SD. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013; 6(4): 676-684. [DOI: 10.1161/CIRCHEARTFAILURE.112.000087]; [PMID: 23733916]